Loading articles...
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
EASL 2026 highlights the evolving role of non-invasive diagnostics in liver disease, offering improved accuracy for fibrosis and steatosis assessment.
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
EASL 2026 data indicates non-invasive markers may reduce liver biopsy necessity for MASH diagnosis, offering a less burdensome alternative.
ATM Germline Mutations and Liver Adenomas in Adolescents: A Clinical Reminder
Young patients with hepatocellular adenomas and no typical risk factors need genetic screening. This can guide surveillance and improve outcomes.